Moderna's mRNA flu shot earns FDA approval after rollercoaster review

Moderna's groundbreaking mRNA flu vaccine, known as mFLUSIVA, has finally received approval from the Food and Drug Administration (FDA) after a tumultuous review process. This achievement marks the first instance of an mRNA-based flu shot receiving FDA approval in the United States. The vaccine, designed for adults aged 50 and above, was approved following a unanimous vote by FDA advisors in June.

This decision was grounded in the vaccine's superior efficacy compared to traditional flu shots, coupled with a strong safety record demonstrated through extensive trials involving nearly 44,000 participants. The FDA had initially set a target date of August 5 for a final decision on the vaccine's approval. While the FDA advisors' unanimous support initially looked promising for Moderna's vaccine, the journey to approval was far from straightforward.

Health Secretary Robert F. Kennedy Jr., a vocal anti-vaccine advocate who has made it his mission to undermine vaccination efforts during his tenure, introduced several obstacles along the way. A prime example was his swift cancellation of a federal campaign promoting flu shots during a particularly harsh flu season. Despite the CDC having already funded this campaign, Kennedy's decision came at a time when the disease was claiming a significant number of young lives.